NCT00309634View on ClinicalTrials.gov

Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years

PHASE1CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

March 27, 2006

Primary Completion Date

October 28, 2006

Study Completion Date

October 28, 2006

Conditions
Influenza
Interventions
BIOLOGICAL

4 adjuvanted pandemic influenza candidate vaccines

BIOLOGICAL

4 non-adjuvanted pandemic influenza candidate vaccines

Trial Locations (1)

9000

GSK Investigational Site, Ghent

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY